Effects of lumacaftor/ivacaftor on cystic fibrosis disease progression in children 2 through 5 years of age homozygous for F508del-CFTR: a phase 2 placebo-controlled clinical trial - Stahl, Mirjam; Roehmel, Jobst; Eichinger, Monika; Doellinger, Felix; Naehrlich, Lutz; Kopp, Matthias V.; Dittrich, Anna-Maria; Lee, Christopher; Sommerburg, Olaf; Tian, Simon; Xu, Tu; Wu, Pan; et al. (Annals of the American Thoracic Society, 2023)
Gesehen am 29.11.2023